NCT06563505View on ClinicalTrials.gov

A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

December 11, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions

Lymphoma

Interventions

DRUG

Mosunetuzumab

Given by IV

DRUG

Zanubrutinib

Given by IV

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER